nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—Prednisone—Crohn's disease	0.633	1	CrCtD
Danazol—Cortisone acetate—Prednisone—Crohn's disease	0.0605	0.284	CrCrCtD
Danazol—Testolactone—Prednisone—Crohn's disease	0.0587	0.275	CrCrCtD
Danazol—Methyltestosterone—Prednisone—Crohn's disease	0.0512	0.24	CrCrCtD
Danazol—Hydrocortisone—Prednisone—Crohn's disease	0.0428	0.201	CrCrCtD
Danazol—AR—scrotum—Crohn's disease	0.00843	0.228	CbGeAlD
Danazol—Peliosis hepatis—Azathioprine—Crohn's disease	0.00474	0.0909	CcSEcCtD
Danazol—AR—penis—Crohn's disease	0.0038	0.103	CbGeAlD
Danazol—Guillain-Barre syndrome—Mesalazine—Crohn's disease	0.00373	0.0716	CcSEcCtD
Danazol—CCL2—gall bladder—Crohn's disease	0.00308	0.0835	CbGeAlD
Danazol—CCL2—mouth—Crohn's disease	0.00274	0.0743	CbGeAlD
Danazol—CCL2—epithelium—Crohn's disease	0.00159	0.0432	CbGeAlD
Danazol—Pigmentation skin—Prednisone—Crohn's disease	0.00157	0.0301	CcSEcCtD
Danazol—CCL2—smooth muscle tissue—Crohn's disease	0.00154	0.0416	CbGeAlD
Danazol—CCL2—skin of body—Crohn's disease	0.00152	0.0411	CbGeAlD
Danazol—CCL2—mammalian vulva—Crohn's disease	0.00138	0.0375	CbGeAlD
Danazol—Polycythaemia—Prednisone—Crohn's disease	0.00131	0.0252	CcSEcCtD
Danazol—Interstitial pneumonia—Azathioprine—Crohn's disease	0.00123	0.0236	CcSEcCtD
Danazol—CCL2—lymphoid tissue—Crohn's disease	0.00123	0.0333	CbGeAlD
Danazol—CCL2—digestive system—Crohn's disease	0.00121	0.0329	CbGeAlD
Danazol—Interstitial pneumonia—Mesalazine—Crohn's disease	0.00112	0.0215	CcSEcCtD
Danazol—Benign intracranial hypertension—Prednisone—Crohn's disease	0.000975	0.0187	CcSEcCtD
Danazol—Hirsutism—Mesalazine—Crohn's disease	0.000932	0.0179	CcSEcCtD
Danazol—Pigmentation disorder—Prednisone—Crohn's disease	0.000859	0.0165	CcSEcCtD
Danazol—Interstitial lung disease—Azathioprine—Crohn's disease	0.00084	0.0161	CcSEcCtD
Danazol—PGR—epithelium—Crohn's disease	0.000838	0.0227	CbGeAlD
Danazol—PGR—smooth muscle tissue—Crohn's disease	0.000808	0.0219	CbGeAlD
Danazol—Thrombosis—Mesalazine—Crohn's disease	0.000765	0.0147	CcSEcCtD
Danazol—Interstitial lung disease—Mesalazine—Crohn's disease	0.000765	0.0147	CcSEcCtD
Danazol—Epilepsy—Prednisone—Crohn's disease	0.000754	0.0144	CcSEcCtD
Danazol—Throat sore—Mesalazine—Crohn's disease	0.000752	0.0144	CcSEcCtD
Danazol—Oropharyngeal discomfort—Mesalazine—Crohn's disease	0.000745	0.0143	CcSEcCtD
Danazol—CCL2—lymph node—Crohn's disease	0.000693	0.0188	CbGeAlD
Danazol—Jaundice cholestatic—Azathioprine—Crohn's disease	0.000677	0.013	CcSEcCtD
Danazol—AR—epithelium—Crohn's disease	0.000668	0.0181	CbGeAlD
Danazol—ESR1—epithelium—Crohn's disease	0.000655	0.0178	CbGeAlD
Danazol—PGR—lymphoid tissue—Crohn's disease	0.000645	0.0175	CbGeAlD
Danazol—Acne—Mesalazine—Crohn's disease	0.000644	0.0123	CcSEcCtD
Danazol—AR—smooth muscle tissue—Crohn's disease	0.000643	0.0174	CbGeAlD
Danazol—AR—skin of body—Crohn's disease	0.000635	0.0172	CbGeAlD
Danazol—ESR1—smooth muscle tissue—Crohn's disease	0.000632	0.0171	CbGeAlD
Danazol—Jaundice cholestatic—Mesalazine—Crohn's disease	0.000617	0.0118	CcSEcCtD
Danazol—Amenorrhoea—Mesalazine—Crohn's disease	0.000617	0.0118	CcSEcCtD
Danazol—Pancreatitis—Mercaptopurine—Crohn's disease	0.000614	0.0118	CcSEcCtD
Danazol—Oropharyngeal pain—Mesalazine—Crohn's disease	0.000596	0.0114	CcSEcCtD
Danazol—AR—mammalian vulva—Crohn's disease	0.000579	0.0157	CbGeAlD
Danazol—Leukocytosis—Mesalazine—Crohn's disease	0.000577	0.011	CcSEcCtD
Danazol—AR—lymphoid tissue—Crohn's disease	0.000514	0.0139	CbGeAlD
Danazol—AR—digestive system—Crohn's disease	0.000508	0.0138	CbGeAlD
Danazol—ESR1—lymphoid tissue—Crohn's disease	0.000505	0.0137	CbGeAlD
Danazol—ESR1—digestive system—Crohn's disease	0.000499	0.0135	CbGeAlD
Danazol—Hepatic function abnormal—Azathioprine—Crohn's disease	0.000494	0.00947	CcSEcCtD
Danazol—Hirsutism—Prednisone—Crohn's disease	0.000493	0.00945	CcSEcCtD
Danazol—CCL2—Methylprednisolone—Prednisone—Crohn's disease	0.000474	0.171	CbGdCrCtD
Danazol—Photosensitivity—Mesalazine—Crohn's disease	0.000448	0.00858	CcSEcCtD
Danazol—Gastroenteritis—Mesalazine—Crohn's disease	0.000444	0.0085	CcSEcCtD
Danazol—Alopecia—Mercaptopurine—Crohn's disease	0.000443	0.00849	CcSEcCtD
Danazol—Leukopenia—Mercaptopurine—Crohn's disease	0.000391	0.00749	CcSEcCtD
Danazol—Migraine—Mesalazine—Crohn's disease	0.000387	0.00742	CcSEcCtD
Danazol—Affect lability—Mesalazine—Crohn's disease	0.000387	0.00742	CcSEcCtD
Danazol—CCL2—Amcinonide—Prednisone—Crohn's disease	0.000376	0.136	CbGdCrCtD
Danazol—Mood swings—Mesalazine—Crohn's disease	0.000373	0.00714	CcSEcCtD
Danazol—Arthralgia—Mercaptopurine—Crohn's disease	0.000372	0.00712	CcSEcCtD
Danazol—Pancreatitis—Azathioprine—Crohn's disease	0.000366	0.00701	CcSEcCtD
Danazol—PGR—lymph node—Crohn's disease	0.000364	0.00987	CbGeAlD
Danazol—Abdominal pain upper—Mesalazine—Crohn's disease	0.000359	0.00688	CcSEcCtD
Danazol—Oedema—Mercaptopurine—Crohn's disease	0.000356	0.00682	CcSEcCtD
Danazol—Cramp muscle—Mesalazine—Crohn's disease	0.000354	0.00679	CcSEcCtD
Danazol—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000349	0.00668	CcSEcCtD
Danazol—Acne—Prednisone—Crohn's disease	0.000341	0.00653	CcSEcCtD
Danazol—Eosinophilia—Mesalazine—Crohn's disease	0.000337	0.00645	CcSEcCtD
Danazol—Pancreatitis—Mesalazine—Crohn's disease	0.000333	0.00639	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00033	0.00632	CcSEcCtD
Danazol—CYP19A1—lymph node—Crohn's disease	0.000328	0.00888	CbGeAlD
Danazol—Amenorrhoea—Prednisone—Crohn's disease	0.000326	0.00625	CcSEcCtD
Danazol—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000324	0.00622	CcSEcCtD
Danazol—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00031	0.00595	CcSEcCtD
Danazol—Weight increased—Mesalazine—Crohn's disease	0.000309	0.00593	CcSEcCtD
Danazol—Leukocytosis—Prednisone—Crohn's disease	0.000305	0.00584	CcSEcCtD
Danazol—Cataract—Prednisone—Crohn's disease	0.000301	0.00577	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.0003	0.00576	CcSEcCtD
Danazol—Haemoglobin—Azathioprine—Crohn's disease	0.0003	0.00575	CcSEcCtD
Danazol—Haemorrhage—Azathioprine—Crohn's disease	0.000299	0.00572	CcSEcCtD
Danazol—Jaundice—Mesalazine—Crohn's disease	0.000295	0.00566	CcSEcCtD
Danazol—CCL2—Fluorometholone—Prednisone—Crohn's disease	0.000294	0.106	CbGdCrCtD
Danazol—Sweating—Mesalazine—Crohn's disease	0.000291	0.00557	CcSEcCtD
Danazol—AR—lymph node—Crohn's disease	0.00029	0.00786	CbGeAlD
Danazol—Haematuria—Mesalazine—Crohn's disease	0.000289	0.00554	CcSEcCtD
Danazol—ESR1—lymph node—Crohn's disease	0.000285	0.00772	CbGeAlD
Danazol—Erythema multiforme—Azathioprine—Crohn's disease	0.000282	0.00541	CcSEcCtD
Danazol—Body temperature increased—Mercaptopurine—Crohn's disease	0.000282	0.0054	CcSEcCtD
Danazol—CYP3A4—digestive system—Crohn's disease	0.000278	0.00754	CbGeAlD
Danazol—Haemoglobin—Mesalazine—Crohn's disease	0.000273	0.00524	CcSEcCtD
Danazol—Fluid retention—Prednisone—Crohn's disease	0.000272	0.00521	CcSEcCtD
Danazol—Haemorrhage—Mesalazine—Crohn's disease	0.000272	0.00521	CcSEcCtD
Danazol—Chills—Azathioprine—Crohn's disease	0.000268	0.00514	CcSEcCtD
Danazol—Alopecia—Azathioprine—Crohn's disease	0.000264	0.00506	CcSEcCtD
Danazol—Erythema multiforme—Mesalazine—Crohn's disease	0.000257	0.00493	CcSEcCtD
Danazol—CCL2—Clobetasol propionate—Prednisone—Crohn's disease	0.000248	0.0897	CbGdCrCtD
Danazol—CCL2—Flunisolide—Prednisone—Crohn's disease	0.000245	0.0885	CbGdCrCtD
Danazol—Chills—Mesalazine—Crohn's disease	0.000244	0.00468	CcSEcCtD
Danazol—CCL2—Triamcinolone—Prednisone—Crohn's disease	0.000243	0.0876	CbGdCrCtD
Danazol—Alopecia—Mesalazine—Crohn's disease	0.00024	0.00461	CcSEcCtD
Danazol—Leukopenia—Azathioprine—Crohn's disease	0.000233	0.00446	CcSEcCtD
Danazol—Tension—Mesalazine—Crohn's disease	0.000232	0.00445	CcSEcCtD
Danazol—CCL2—Desoximetasone—Prednisone—Crohn's disease	0.00023	0.0832	CbGdCrCtD
Danazol—Nervousness—Mesalazine—Crohn's disease	0.00023	0.00441	CcSEcCtD
Danazol—Back pain—Mesalazine—Crohn's disease	0.000229	0.00439	CcSEcCtD
Danazol—Muscle spasms—Mesalazine—Crohn's disease	0.000228	0.00436	CcSEcCtD
Danazol—Vomiting—Mercaptopurine—Crohn's disease	0.000226	0.00434	CcSEcCtD
Danazol—Rash—Mercaptopurine—Crohn's disease	0.000225	0.0043	CcSEcCtD
Danazol—Dermatitis—Mercaptopurine—Crohn's disease	0.000224	0.0043	CcSEcCtD
Danazol—CCL2—Diflorasone—Prednisone—Crohn's disease	0.000224	0.0808	CbGdCrCtD
Danazol—Vision blurred—Mesalazine—Crohn's disease	0.000223	0.00428	CcSEcCtD
Danazol—Tremor—Mesalazine—Crohn's disease	0.000222	0.00425	CcSEcCtD
Danazol—Arthralgia—Azathioprine—Crohn's disease	0.000221	0.00424	CcSEcCtD
Danazol—Vertigo—Mesalazine—Crohn's disease	0.000213	0.00408	CcSEcCtD
Danazol—Syncope—Mesalazine—Crohn's disease	0.000212	0.00407	CcSEcCtD
Danazol—Leukopenia—Mesalazine—Crohn's disease	0.000212	0.00406	CcSEcCtD
Danazol—Nausea—Mercaptopurine—Crohn's disease	0.000212	0.00405	CcSEcCtD
Danazol—Palpitations—Mesalazine—Crohn's disease	0.000209	0.00401	CcSEcCtD
Danazol—Loss of consciousness—Mesalazine—Crohn's disease	0.000208	0.00399	CcSEcCtD
Danazol—Thrombocytopenia—Azathioprine—Crohn's disease	0.000208	0.00398	CcSEcCtD
Danazol—Affect lability—Prednisone—Crohn's disease	0.000205	0.00392	CcSEcCtD
Danazol—Hypertension—Mesalazine—Crohn's disease	0.000204	0.00392	CcSEcCtD
Danazol—Arthralgia—Mesalazine—Crohn's disease	0.000202	0.00386	CcSEcCtD
Danazol—Anxiety—Mesalazine—Crohn's disease	0.000201	0.00385	CcSEcCtD
Danazol—Irritability—Prednisone—Crohn's disease	0.000199	0.00381	CcSEcCtD
Danazol—Mood swings—Prednisone—Crohn's disease	0.000197	0.00378	CcSEcCtD
Danazol—CCL2—Budesonide—Prednisone—Crohn's disease	0.000196	0.0708	CbGdCrCtD
Danazol—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000193	0.0037	CcSEcCtD
Danazol—Oedema—Mesalazine—Crohn's disease	0.000193	0.0037	CcSEcCtD
Danazol—Shock—Mesalazine—Crohn's disease	0.00019	0.00364	CcSEcCtD
Danazol—Thrombocytopenia—Mesalazine—Crohn's disease	0.000189	0.00363	CcSEcCtD
Danazol—Tachycardia—Mesalazine—Crohn's disease	0.000189	0.00362	CcSEcCtD
Danazol—Hyperhidrosis—Mesalazine—Crohn's disease	0.000187	0.00358	CcSEcCtD
Danazol—Pancreatitis—Prednisone—Crohn's disease	0.000176	0.00338	CcSEcCtD
Danazol—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000176	0.00337	CcSEcCtD
Danazol—Paraesthesia—Mesalazine—Crohn's disease	0.000174	0.00333	CcSEcCtD
Danazol—Dyspepsia—Mesalazine—Crohn's disease	0.00017	0.00326	CcSEcCtD
Danazol—Body temperature increased—Azathioprine—Crohn's disease	0.000168	0.00321	CcSEcCtD
Danazol—Fatigue—Mesalazine—Crohn's disease	0.000167	0.00319	CcSEcCtD
Danazol—CCL2—Oncostatin M Signaling Pathway—STAT3—Crohn's disease	0.000167	0.0027	CbGpPWpGaD
Danazol—Constipation—Mesalazine—Crohn's disease	0.000165	0.00317	CcSEcCtD
Danazol—CCL2—TWEAK Signaling Pathway—IL6—Crohn's disease	0.000165	0.00267	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—ACKR2—Crohn's disease	0.000164	0.00266	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000164	0.00265	CbGpPWpGaD
Danazol—Weight increased—Prednisone—Crohn's disease	0.000164	0.00314	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000161	0.00261	CbGpPWpGaD
Danazol—Acute coronary syndrome—Prednisone—Crohn's disease	0.000158	0.00303	CcSEcCtD
Danazol—Myocardial infarction—Prednisone—Crohn's disease	0.000157	0.00301	CcSEcCtD
Danazol—GNRHR—GPCR downstream signaling—MLN—Crohn's disease	0.000157	0.00254	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IL1B—Crohn's disease	0.000156	0.00253	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—MLN—Crohn's disease	0.000156	0.00252	CbGpPWpGaD
Danazol—Urticaria—Mesalazine—Crohn's disease	0.000154	0.00294	CcSEcCtD
Danazol—Body temperature increased—Mesalazine—Crohn's disease	0.000153	0.00293	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—ACKR2—Crohn's disease	0.00015	0.00243	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000147	0.00238	CbGpPWpGaD
Danazol—Testosterone—SLC22A4—Crohn's disease	0.000145	0.429	CrCbGaD
Danazol—Haemoglobin—Prednisone—Crohn's disease	0.000145	0.00277	CcSEcCtD
Danazol—Haemorrhage—Prednisone—Crohn's disease	0.000144	0.00276	CcSEcCtD
Danazol—CCL2—Folate Metabolism—TNF—Crohn's disease	0.000142	0.00231	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—MLN—Crohn's disease	0.000142	0.0023	CbGpPWpGaD
Danazol—CCL2—Vitamin B12 Metabolism—IL6—Crohn's disease	0.000141	0.00229	CbGpPWpGaD
Danazol—Dizziness—Azathioprine—Crohn's disease	0.00014	0.00269	CcSEcCtD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—IL10—Crohn's disease	0.00014	0.00226	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CCR6—Crohn's disease	0.000139	0.00225	CbGpPWpGaD
Danazol—Asthenia—Mesalazine—Crohn's disease	0.000139	0.00266	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—IFNG—Crohn's disease	0.000138	0.00224	CbGpPWpGaD
Danazol—Pruritus—Mesalazine—Crohn's disease	0.000137	0.00262	CcSEcCtD
Danazol—CYP19A1—Metapathway biotransformation—GPX4—Crohn's disease	0.000136	0.0022	CbGpPWpGaD
Danazol—Vomiting—Azathioprine—Crohn's disease	0.000135	0.00259	CcSEcCtD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—SMAD3—Crohn's disease	0.000134	0.00218	CbGpPWpGaD
Danazol—Rash—Azathioprine—Crohn's disease	0.000134	0.00256	CcSEcCtD
Danazol—Dermatitis—Azathioprine—Crohn's disease	0.000134	0.00256	CcSEcCtD
Danazol—Flushing—Prednisone—Crohn's disease	0.000134	0.00256	CcSEcCtD
Danazol—Headache—Azathioprine—Crohn's disease	0.000133	0.00255	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—PTGS2—Crohn's disease	0.000133	0.00215	CbGpPWpGaD
Danazol—AR—Notch-mediated HES/HEY network—JAK2—Crohn's disease	0.000129	0.00209	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—CXCL8—Crohn's disease	0.000129	0.00208	CbGpPWpGaD
Danazol—Dizziness—Mesalazine—Crohn's disease	0.000128	0.00245	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCR6—Crohn's disease	0.000127	0.00206	CbGpPWpGaD
Danazol—Alopecia—Prednisone—Crohn's disease	0.000127	0.00244	CcSEcCtD
Danazol—Nausea—Azathioprine—Crohn's disease	0.000126	0.00242	CcSEcCtD
Danazol—AR—Androgen receptor signaling pathway—SMAD3—Crohn's disease	0.000125	0.00202	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IL1B—Crohn's disease	0.000123	0.002	CbGpPWpGaD
Danazol—Vomiting—Mesalazine—Crohn's disease	0.000123	0.00236	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—PTGER4—Crohn's disease	0.000123	0.00199	CbGpPWpGaD
Danazol—AR—Notch-mediated HES/HEY network—CD4—Crohn's disease	0.000123	0.00198	CbGpPWpGaD
Danazol—Rash—Mesalazine—Crohn's disease	0.000122	0.00234	CcSEcCtD
Danazol—Dermatitis—Mesalazine—Crohn's disease	0.000122	0.00233	CcSEcCtD
Danazol—Headache—Mesalazine—Crohn's disease	0.000121	0.00232	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—IL10—Crohn's disease	0.000121	0.00196	CbGpPWpGaD
Danazol—CCL2—Dexamethasone—Prednisone—Crohn's disease	0.00012	0.0433	CbGdCrCtD
Danazol—CCL2—Betamethasone—Prednisone—Crohn's disease	0.00012	0.0433	CbGdCrCtD
Danazol—ESR1—Regulation of Telomerase—SMAD3—Crohn's disease	0.000119	0.00193	CbGpPWpGaD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—Crohn's disease	0.000119	0.00192	CbGpPWpGaD
Danazol—Vision blurred—Prednisone—Crohn's disease	0.000118	0.00226	CcSEcCtD
Danazol—ESR1—Nuclear signaling by ERBB4—JAK2—Crohn's disease	0.000116	0.00187	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—IL6—Crohn's disease	0.000115	0.00186	CbGpPWpGaD
Danazol—Nausea—Mesalazine—Crohn's disease	0.000115	0.0022	CcSEcCtD
Danazol—CCL2—Selenium Micronutrient Network—TNF—Crohn's disease	0.000113	0.00183	CbGpPWpGaD
Danazol—Vertigo—Prednisone—Crohn's disease	0.000113	0.00216	CcSEcCtD
Danazol—Syncope—Prednisone—Crohn's disease	0.000112	0.00215	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—PTGER4—Crohn's disease	0.000112	0.00182	CbGpPWpGaD
Danazol—Loss of consciousness—Prednisone—Crohn's disease	0.00011	0.00211	CcSEcCtD
Danazol—CCL2—AP-1 transcription factor network—IL6—Crohn's disease	0.00011	0.00178	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—TNF—Crohn's disease	0.000109	0.00177	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CCR9—Crohn's disease	0.000109	0.00176	CbGpPWpGaD
Danazol—Convulsion—Prednisone—Crohn's disease	0.000109	0.00208	CcSEcCtD
Danazol—Hypertension—Prednisone—Crohn's disease	0.000108	0.00207	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—CCR9—Crohn's disease	0.000108	0.00175	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—Crohn's disease	0.000108	0.00174	CbGpPWpGaD
Danazol—Arthralgia—Prednisone—Crohn's disease	0.000107	0.00204	CcSEcCtD
Danazol—Anxiety—Prednisone—Crohn's disease	0.000106	0.00204	CcSEcCtD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—SMAD3—Crohn's disease	0.000104	0.00168	CbGpPWpGaD
Danazol—Oedema—Prednisone—Crohn's disease	0.000102	0.00196	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	0.000102	0.00165	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—GPR65—Crohn's disease	0.000101	0.00164	CbGpPWpGaD
Danazol—Shock—Prednisone—Crohn's disease	0.000101	0.00193	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—GPR65—Crohn's disease	0.0001	0.00162	CbGpPWpGaD
Danazol—Tachycardia—Prednisone—Crohn's disease	9.98e-05	0.00191	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—RBX1—Crohn's disease	9.97e-05	0.00162	CbGpPWpGaD
Danazol—Hyperhidrosis—Prednisone—Crohn's disease	9.89e-05	0.00189	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—CCR9—Crohn's disease	9.86e-05	0.0016	CbGpPWpGaD
Danazol—PGR—Gene Expression—PTRF—Crohn's disease	9.84e-05	0.00159	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ACKR2—Crohn's disease	9.7e-05	0.00157	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	9.53e-05	0.00154	CbGpPWpGaD
Danazol—AR—Notch-mediated HES/HEY network—STAT3—Crohn's disease	9.49e-05	0.00154	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Prednisone—Crohn's disease	9.32e-05	0.00179	CcSEcCtD
Danazol—CCL2—Signaling Pathways—MLN—Crohn's disease	9.19e-05	0.00149	CbGpPWpGaD
Danazol—Paraesthesia—Prednisone—Crohn's disease	9.18e-05	0.00176	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—GPR65—Crohn's disease	9.17e-05	0.00149	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IL6—Crohn's disease	9.13e-05	0.00148	CbGpPWpGaD
Danazol—Dyspepsia—Prednisone—Crohn's disease	9e-05	0.00173	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—TNF—Crohn's disease	8.95e-05	0.00145	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	8.94e-05	0.00145	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ACKR2—Crohn's disease	8.87e-05	0.00144	CbGpPWpGaD
Danazol—Fatigue—Prednisone—Crohn's disease	8.82e-05	0.00169	CcSEcCtD
Danazol—CCL2—TNF alpha Signaling Pathway—IL6—Crohn's disease	8.81e-05	0.00143	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	8.79e-05	0.00142	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—CXCL8—Crohn's disease	8.78e-05	0.00142	CbGpPWpGaD
Danazol—Constipation—Prednisone—Crohn's disease	8.75e-05	0.00168	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	8.54e-05	0.00138	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TAGAP—Crohn's disease	8.41e-05	0.00136	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MLN—Crohn's disease	8.41e-05	0.00136	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	8.36e-05	0.00135	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL10—Crohn's disease	8.26e-05	0.00134	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—IFNG—Crohn's disease	8.15e-05	0.00132	CbGpPWpGaD
Danazol—Urticaria—Prednisone—Crohn's disease	8.12e-05	0.00156	CcSEcCtD
Danazol—Body temperature increased—Prednisone—Crohn's disease	8.09e-05	0.00155	CcSEcCtD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	7.97e-05	0.00129	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	7.87e-05	0.00127	CbGpPWpGaD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—Crohn's disease	7.71e-05	0.00125	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TAGAP—Crohn's disease	7.69e-05	0.00125	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—CXCL8—Crohn's disease	7.58e-05	0.00123	CbGpPWpGaD
Danazol—AR—Gene Expression—PTRF—Crohn's disease	7.5e-05	0.00121	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RSPO3—Crohn's disease	7.35e-05	0.00119	CbGpPWpGaD
Danazol—Asthenia—Prednisone—Crohn's disease	7.34e-05	0.00141	CcSEcCtD
Danazol—ESR1—Regulation of Telomerase—IFNG—Crohn's disease	7.27e-05	0.00118	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.26e-05	0.00118	CbGpPWpGaD
Danazol—Pruritus—Prednisone—Crohn's disease	7.24e-05	0.00139	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—IL6—Crohn's disease	7.22e-05	0.00117	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CCR6—Crohn's disease	7.2e-05	0.00117	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CCR6—Crohn's disease	7.14e-05	0.00116	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IFNG—Crohn's disease	7.11e-05	0.00115	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SEL1L—Crohn's disease	6.97e-05	0.00113	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—TYK2—Crohn's disease	6.95e-05	0.00113	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	6.89e-05	0.00112	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—JAK2—Crohn's disease	6.85e-05	0.00111	CbGpPWpGaD
Danazol—Dizziness—Prednisone—Crohn's disease	6.76e-05	0.0013	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—RSPO3—Crohn's disease	6.72e-05	0.00109	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—JAK2—Crohn's disease	6.63e-05	0.00107	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—CXCL8—Crohn's disease	6.61e-05	0.00107	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCR6—Crohn's disease	6.53e-05	0.00106	CbGpPWpGaD
Danazol—Vomiting—Prednisone—Crohn's disease	6.5e-05	0.00125	CcSEcCtD
Danazol—Rash—Prednisone—Crohn's disease	6.45e-05	0.00124	CcSEcCtD
Danazol—Dermatitis—Prednisone—Crohn's disease	6.44e-05	0.00123	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	6.44e-05	0.00104	CbGpPWpGaD
Danazol—Headache—Prednisone—Crohn's disease	6.41e-05	0.00123	CcSEcCtD
Danazol—CCL2—Signaling Pathways—CCR9—Crohn's disease	6.37e-05	0.00103	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SEL1L—Crohn's disease	6.37e-05	0.00103	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—PTGER4—Crohn's disease	6.33e-05	0.00103	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PTGER4—Crohn's disease	6.29e-05	0.00102	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—UBE2D1—Crohn's disease	6.17e-05	0.000999	CbGpPWpGaD
Danazol—Nausea—Prednisone—Crohn's disease	6.08e-05	0.00116	CcSEcCtD
Danazol—ESR1—Leptin signaling pathway—IL1B—Crohn's disease	6e-05	0.000972	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—GPR65—Crohn's disease	5.92e-05	0.000959	CbGpPWpGaD
Danazol—PGR—Gene Expression—ZFP36L1—Crohn's disease	5.89e-05	0.000955	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	5.89e-05	0.000954	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCR9—Crohn's disease	5.83e-05	0.000944	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PTRF—Crohn's disease	5.77e-05	0.000935	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PTGER4—Crohn's disease	5.75e-05	0.000932	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—STAT3—Crohn's disease	5.69e-05	0.000922	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.65e-05	0.000916	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ACKR2—Crohn's disease	5.59e-05	0.000906	CbGpPWpGaD
Danazol—Prednisone—ALB—Crohn's disease	5.57e-05	0.165	CrCbGaD
Danazol—Norethindrone—ALB—Crohn's disease	5.49e-05	0.162	CrCbGaD
Danazol—GNRHR—Signaling Pathways—GPR65—Crohn's disease	5.42e-05	0.000877	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL3—Crohn's disease	5.4e-05	0.000874	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	5.39e-05	0.000873	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL3—Crohn's disease	5.36e-05	0.000868	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MLN—Crohn's disease	5.3e-05	0.000859	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.29e-05	0.000858	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—RASGRP1—Crohn's disease	5.22e-05	0.000845	CbGpPWpGaD
Danazol—Methyltestosterone—ALB—Crohn's disease	5.22e-05	0.154	CrCbGaD
Danazol—CCL2—Signaling by GPCR—RASGRP1—Crohn's disease	5.18e-05	0.000839	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—STAT3—Crohn's disease	5.03e-05	0.000815	CbGpPWpGaD
Danazol—PGR—Gene Expression—DNMT3A—Crohn's disease	5.01e-05	0.000812	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL3—Crohn's disease	4.9e-05	0.000794	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TAGAP—Crohn's disease	4.85e-05	0.000785	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—RASGRP1—Crohn's disease	4.74e-05	0.000768	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—UBE2D1—Crohn's disease	4.7e-05	0.000761	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	4.52e-05	0.000732	CbGpPWpGaD
Danazol—AR—Gene Expression—ZFP36L1—Crohn's disease	4.49e-05	0.000727	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—CXCL8—Crohn's disease	4.49e-05	0.000727	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—SMAD3—Crohn's disease	4.41e-05	0.000714	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL1B—Crohn's disease	4.33e-05	0.000702	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—IL6—Crohn's disease	4.26e-05	0.000689	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RSPO3—Crohn's disease	4.24e-05	0.000686	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCR6—Crohn's disease	4.22e-05	0.000684	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—CXCL8—Crohn's disease	4.1e-05	0.000665	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	4.09e-05	0.000662	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—TYK2—Crohn's disease	4.08e-05	0.000661	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SEL1L—Crohn's disease	4.02e-05	0.000651	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	3.97e-05	0.000643	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.96e-05	0.000642	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—JAK2—Crohn's disease	3.89e-05	0.000631	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCR6—Crohn's disease	3.86e-05	0.000625	CbGpPWpGaD
Danazol—AR—Gene Expression—DNMT3A—Crohn's disease	3.82e-05	0.000619	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RBX1—Crohn's disease	3.82e-05	0.000618	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PLA2G4F—Crohn's disease	3.8e-05	0.000616	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL2RA—Crohn's disease	3.78e-05	0.000612	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL2RA—Crohn's disease	3.75e-05	0.000608	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTGER4—Crohn's disease	3.72e-05	0.000602	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IL6—Crohn's disease	3.71e-05	0.000601	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCR9—Crohn's disease	3.67e-05	0.000595	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—UBE2D1—Crohn's disease	3.62e-05	0.000586	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RBX1—Crohn's disease	3.49e-05	0.000565	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ZFP36L1—Crohn's disease	3.46e-05	0.00056	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL2RA—Crohn's disease	3.43e-05	0.000556	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GPR65—Crohn's disease	3.42e-05	0.000553	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—IL6—Crohn's disease	3.4e-05	0.000551	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTGER4—Crohn's disease	3.4e-05	0.00055	CbGpPWpGaD
Danazol—PGR—Gene Expression—HSPA1B—Crohn's disease	3.39e-05	0.000548	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—SMAD3—Crohn's disease	3.36e-05	0.000544	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—UBE2D1—Crohn's disease	3.35e-05	0.000542	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ACKR2—Crohn's disease	3.28e-05	0.000532	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RIPK2—Crohn's disease	3.25e-05	0.000526	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—MTMR3—Crohn's disease	3.23e-05	0.000524	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL3—Crohn's disease	3.16e-05	0.000513	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—CXCL8—Crohn's disease	3.16e-05	0.000511	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—TNF—Crohn's disease	3.15e-05	0.000509	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MLN—Crohn's disease	3.11e-05	0.000504	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RASGRP1—Crohn's disease	3.06e-05	0.000496	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—UBE2D1—Crohn's disease	3.06e-05	0.000496	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.05e-05	0.000494	CbGpPWpGaD
Danazol—Testosterone—ALB—Crohn's disease	3.03e-05	0.0894	CrCbGaD
Danazol—PGR—Gene Expression—UBE2D1—Crohn's disease	2.97e-05	0.000481	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RIPK2—Crohn's disease	2.97e-05	0.000481	CbGpPWpGaD
Danazol—ESR1—Gene Expression—DNMT3A—Crohn's disease	2.94e-05	0.000476	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL3—Crohn's disease	2.89e-05	0.000469	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TAGAP—Crohn's disease	2.85e-05	0.000461	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RASGRP1—Crohn's disease	2.8e-05	0.000453	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SOCS1—Crohn's disease	2.77e-05	0.000449	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.68e-05	0.000433	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—TYK2—Crohn's disease	2.64e-05	0.000428	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—SMAD3—Crohn's disease	2.59e-05	0.000419	CbGpPWpGaD
Danazol—AR—Gene Expression—HSPA1B—Crohn's disease	2.58e-05	0.000418	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—JAK2—Crohn's disease	2.54e-05	0.000411	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL6—Crohn's disease	2.54e-05	0.000411	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SOCS1—Crohn's disease	2.54e-05	0.000411	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—JAK2—Crohn's disease	2.52e-05	0.000409	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—FADS1—Crohn's disease	2.52e-05	0.000408	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RSPO3—Crohn's disease	2.49e-05	0.000403	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCR6—Crohn's disease	2.43e-05	0.000394	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—TYK2—Crohn's disease	2.42e-05	0.000392	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SMAD3—Crohn's disease	2.39e-05	0.000388	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GPX4—Crohn's disease	2.36e-05	0.000382	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SEL1L—Crohn's disease	2.36e-05	0.000382	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCL8—Crohn's disease	2.32e-05	0.000376	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—JAK2—Crohn's disease	2.31e-05	0.000374	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL8—Crohn's disease	2.3e-05	0.000373	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GCKR—Crohn's disease	2.28e-05	0.000369	CbGpPWpGaD
Danazol—AR—Gene Expression—UBE2D1—Crohn's disease	2.26e-05	0.000366	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL2RA—Crohn's disease	2.22e-05	0.000359	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RBX1—Crohn's disease	2.2e-05	0.000357	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SMAD3—Crohn's disease	2.19e-05	0.000355	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCR9—Crohn's disease	2.16e-05	0.000349	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTGER4—Crohn's disease	2.14e-05	0.000347	CbGpPWpGaD
Danazol—PGR—Gene Expression—SMAD3—Crohn's disease	2.12e-05	0.000344	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL8—Crohn's disease	2.11e-05	0.000341	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.06e-05	0.000334	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL2RA—Crohn's disease	2.03e-05	0.000328	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GPR65—Crohn's disease	2e-05	0.000325	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—IL6—Crohn's disease	2e-05	0.000323	CbGpPWpGaD
Danazol—ESR1—Gene Expression—HSPA1B—Crohn's disease	1.99e-05	0.000322	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—UBE2D1—Crohn's disease	1.93e-05	0.000313	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RIPK2—Crohn's disease	1.87e-05	0.000303	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL3—Crohn's disease	1.83e-05	0.000296	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RASGRP1—Crohn's disease	1.77e-05	0.000286	CbGpPWpGaD
Danazol—ESR1—Gene Expression—UBE2D1—Crohn's disease	1.74e-05	0.000282	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.63e-05	0.000264	CbGpPWpGaD
Danazol—AR—Gene Expression—SMAD3—Crohn's disease	1.62e-05	0.000262	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SOCS1—Crohn's disease	1.6e-05	0.000259	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TYK2—Crohn's disease	1.56e-05	0.000253	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—JAK2—Crohn's disease	1.49e-05	0.000241	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TYK2—Crohn's disease	1.43e-05	0.000231	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCR6—Crohn's disease	1.43e-05	0.000231	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.42e-05	0.000231	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMAD3—Crohn's disease	1.38e-05	0.000224	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—JAK2—Crohn's disease	1.36e-05	0.000221	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL8—Crohn's disease	1.36e-05	0.00022	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL6—Crohn's disease	1.29e-05	0.000209	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RBX1—Crohn's disease	1.29e-05	0.000209	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL2RA—Crohn's disease	1.28e-05	0.000207	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTGER4—Crohn's disease	1.26e-05	0.000204	CbGpPWpGaD
Danazol—ESR1—Gene Expression—SMAD3—Crohn's disease	1.25e-05	0.000202	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL8—Crohn's disease	1.24e-05	0.000201	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL6—Crohn's disease	1.18e-05	0.000192	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—UBE2D1—Crohn's disease	1.13e-05	0.000183	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.11e-05	0.00018	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RIPK2—Crohn's disease	1.1e-05	0.000178	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—STAT3—Crohn's disease	1.09e-05	0.000177	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL3—Crohn's disease	1.07e-05	0.000174	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RASGRP1—Crohn's disease	1.04e-05	0.000168	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—STAT3—Crohn's disease	1e-05	0.000162	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—MTMR3—Crohn's disease	9.43e-06	0.000153	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SOCS1—Crohn's disease	9.39e-06	0.000152	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TYK2—Crohn's disease	9.01e-06	0.000146	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—JAK2—Crohn's disease	8.59e-06	0.000139	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMAD3—Crohn's disease	8.1e-06	0.000131	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL8—Crohn's disease	7.84e-06	0.000127	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL6—Crohn's disease	7.64e-06	0.000124	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL2RA—Crohn's disease	7.5e-06	0.000122	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—FADS1—Crohn's disease	7.35e-06	0.000119	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ALB—Crohn's disease	7.25e-06	0.000117	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL6—Crohn's disease	6.99e-06	0.000113	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GPX4—Crohn's disease	6.88e-06	0.000111	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GCKR—Crohn's disease	6.65e-06	0.000108	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTGS2—Crohn's disease	6.34e-06	0.000103	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—STAT3—Crohn's disease	6.31e-06	0.000102	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TYK2—Crohn's disease	5.29e-06	8.56e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—JAK2—Crohn's disease	5.04e-06	8.17e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL8—Crohn's disease	4.6e-06	7.46e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL6—Crohn's disease	4.41e-06	7.14e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—STAT3—Crohn's disease	3.7e-06	6e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL6—Crohn's disease	2.59e-06	4.19e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ALB—Crohn's disease	2.12e-06	3.43e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.85e-06	3e-05	CbGpPWpGaD
